Thus far in the calendar year 2025, the stock price of GSK Pharma has zoomed 40 per cent, as against 1.8 per cent rise in BSE ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Shareholders have already approved a pay increase for British American Tobacco chief executive Tadeu Marroco. He could ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2916. The stock has experienced fluctuations ...

Vir Biotechnology, Inc.’s VIR share price has surged by 5.82%, which has investors questioning if this is right time to sell.

GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...